Status:
UNKNOWN
To Study the Function of the Retina in Glaucoma Patients Using PERG
Lead Sponsor:
Swiss Vision Network
Conditions:
Glaucoma
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this trial is to evaluate the performance of a new diagnostic device in the diagnosis and management of glaucoma. We will use this new device (PERG) to evaluate the function of the reti...
Detailed Description
Glaucoma is one of the leading causes of blindness worldwide. It's an optic neuropathy characterized by the progressive death of retinal ganglion cells. In laboratories, it's possible to measure the ...
Eligibility Criteria
Inclusion
- Glaucoma (all types of glaucoma);
- Ocular hypertensive (Suspicion of glaucoma);
- Control Patients (without any suspicion/sign of glaucoma);
- Have given written informed consent, prior to any investigational procedures;
- Aged 18 years of either sex.
Exclusion
- Patients not able to understand the character of the study
- Participation in other clinical research within the last 4 weeks
- Other diseases that may cause visual field loss or optic disc abnormalities
- Systemic diseases that may affect PERG amplitude such as diabetes, parkinsonism, multiple sclerosis
- Poor best corrected visual acuity outside the limits recommended for the test
- Patients with high myopia (\>5D)
Key Trial Info
Start Date :
January 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT03330574
Start Date
January 1 2017
End Date
December 1 2023
Last Update
May 5 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Montchoisi Clinic
Lausanne, Canton of Vaud, Switzerland, 1006